A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2022
This article has no abstract
Epistemonikos ID: ff0c3a33739e3631ca33e2ac272038d768f39c8c
First added on: Apr 11, 2025